# A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer

> **NCT05179239** · PHASE3 · TERMINATED · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 31 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102
- **DRUG:** SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102
- **DRUG:** Placebo + paclitaxel + cisplatin/carboplatin ± BP102

## Key facts

- **NCT ID:** NCT05179239
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-26
- **Primary completion:** 2024-08-12
- **Final completion:** 2024-08-12
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Sponsor develops strategy adjustment
- **Last updated:** 2025-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05179239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05179239, "A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05179239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*